 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- ||| surzebiclimab (BGB-A425) / BeiGene, Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Trial completion: BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - Feb 14, 2025
P1/2, N=114, Completed, Sponsor: BeiGene
Active, not recruiting --> Completed
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - Jan 15, 2025
P1, N=88, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Active, not recruiting --> Completed Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Jul 2025
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment closed: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 15, 2025
P2, N=400, Active, not recruiting, Sponsor: BeiGene
Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Jul 2025 Recruiting --> Active, not recruiting
- ||| surzebiclimab (BGB-A425) / BeiGene, Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Enrollment closed, Enrollment change: BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - Jan 10, 2025
P1/2, N=114, Active, not recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=358 --> 114
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Mismatch repair: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 4, 2025
P1/2, N=113, Active, not recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting | N=358 --> 114 Recruiting --> Active, not recruiting | N=226 --> 113 | Trial completion date: Apr 2028 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=200, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Recruiting --> Active, not recruiting | N=226 --> 113 | Trial completion date: Apr 2028 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026 Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- || Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment closed: BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 27, 2024
P2, N=160, Active, not recruiting, Sponsor: BeiGene
Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 Recruiting --> Active, not recruiting
- || Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment closed, Monotherapy: BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 31, 2024
P2, N=121, Active, not recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov) - Oct 24, 2024
P1/2, N=490, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Recruiting --> Active, not recruiting Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- || surzebiclimab (BGB-A425) / BeiGene, Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2024
P1/2, N=358, Recruiting, Sponsor: BeiGene
Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=88, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025 Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Aug 16, 2024
P1/2, N=200, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Mar 2025 Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
- | alcestobart (LBL-007) / BeiGene
Trial completion, Enrollment change, IO biomarker: Anti-LAG-3 Monoclonal Antibody Injection (LBL-007) Phase Ia Clinical Trial of Safety, Tolerance, Pharmacokinetics and Effectiveness in Patients with Advanced Solid Tumors and Advanced Lymphomas (EUDRACT) - Jul 16, 2024
P1, N=22, Completed, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Leads Biolabs Co., Ltd.
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Dec 2024 Not yet recruiting --> Completed | N=36 --> 22
- || Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Enrollment closed: BGB-A317-LBL-007-202: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - May 31, 2024
P2, N=118, Active, not recruiting, Sponsor: BeiGene
Not yet recruiting --> Completed | N=36 --> 22 Recruiting --> Active, not recruiting
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - May 15, 2024
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Recruiting --> Active, not recruiting Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
- Tevimbra (tislelizumab-jsgr) / BeiGene, LBL-007 / BeiGene
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study. (Hall A; Poster Bd #: 336) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3484;
P1/2
LBL-007/tislelizumab/GC combination showed manageable, no new safety concerns and encouraging antitumor activity in previously untreated and advanced NPC patients. The encouraging efficacy and safety profile may support a pivotal study with LBL-007 in combination with tislelizumab and GC chemotherapy for NPC development in 1L setting.
- Tevimbra (tislelizumab) / BeiGene
BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7908;
P2
The encouraging efficacy and safety profile may support a pivotal study with LBL-007 in combination with tislelizumab and GC chemotherapy for NPC development in 1L setting. Abstract is embargoed at this time.
- Liberty-201: Maintenance fluoropyrimidine and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7907;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- Tevimbra (tislelizumab) / BeiGene
BGB?A317?LBL?007?202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL?007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7905;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- surzebiclimab (BGB-A425) / BeiGene, Tevimbra (tislelizumab) / BeiGene, LBL-007 / BeiGene
Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC (Section 3) - Mar 5, 2024 - Abstract #AACR2024AACR_6915;
P2
The results demonstrated the therapeutic potential of the triple combination. A Ph2 study evaluating Tisle in combination with LBL-007 and/or Surze in first-line treatment of recurrent or metastatic HNSCC (NCT05909904) is recruiting.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, LBL-007 / BeiGene
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6671;
A Ph2 study evaluating Tisle in combination with LBL-007 and/or Surze in first-line treatment of recurrent or metastatic HNSCC (NCT05909904) is recruiting. Abstract is embargoed at this time.
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 7, 2024
P2, N=400, Recruiting, Sponsor: BeiGene
Abstract is embargoed at this time. N=200 --> 400
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - Jan 3, 2024
P1, N=88, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
N=200 --> 400 Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Jan 3, 2024
P1/2, N=200, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2024 Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
- || Tevimbra (tislelizumab-jsgr) / BeiGene
Trial completion date, Trial primary completion date: BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 6, 2023
P2, N=160, Recruiting, Sponsor: BeiGene
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 6, 2023
P2, N=120, Recruiting, Sponsor: BeiGene
Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jul 2024 N=90 --> 120
- | Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Phase classification, Mismatch repair: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2023
P1/2, N=226, Recruiting, Sponsor: BeiGene
N=90 --> 120 Phase classification: P1b/2 --> P1/2
- || Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: BGB-A317-LBL-007-202: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 3, 2023
P2, N=116, Recruiting, Sponsor: BeiGene
Phase classification: P1b/2 --> P1/2 .
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Enrollment open: BGB-A317-LBL-007-202: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 13, 2023
P2, N=116, Recruiting, Sponsor: BeiGene
. Not yet recruiting --> Recruiting
- Tevimbra (tislelizumab) / BeiGene
BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC) (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_996;
P2
Secondary endpoints include pathological complete response per BIPR, overall survival, event-free survival, and disease-free survival (both per investigator; RECIST v1.1), adverse events (per CTCAE v5.0), the proportion of pts who undergo surgical resection following treatment, and pharmacodynamic assessments of the investigational agents. Enrollment is ongoing.
- || Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion date, Trial primary completion date, Mismatch repair, IO biomarker: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 1, 2023
P1b/2, N=226, Recruiting, Sponsor: BeiGene
Enrollment is ongoing. Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Feb 2025 --> Apr 2028
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
New P2 trial: BGB-A317-LBL-007-202: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 24, 2023
P2, N=116, Not yet recruiting, Sponsor: BeiGene
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment open, Mismatch repair, IO biomarker: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2023
P1b/2, N=202, Recruiting, Sponsor: BeiGene
Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Feb 2025 --> Apr 2028 Active, not recruiting --> Recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open: BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 27, 2023
P2, N=160, Recruiting, Sponsor: BeiGene
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial: BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 18, 2023
P2, N=160, Not yet recruiting, Sponsor: BeiGene
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Jun 6, 2023
P1/2, N=200, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Not yet recruiting --> Recruiting Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
- || alcestobart (LBL-007) / BeiGene
Trial completion date, Trial primary completion date: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - Jun 6, 2023
P1, N=88, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Dec 2023 Trial completion date: Aug 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Dec 2023
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed, Mismatch repair, IO biomarker: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 1, 2023
P1b/2, N=202, Active, not recruiting, Sponsor: BeiGene
Trial completion date: Aug 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 23, 2023
P2, N=200, Recruiting, Sponsor: BeiGene
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
- Inlyta (axitinib) / Pfizer, Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, LBL-007 / BeiGene
Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma. (On Demand | Hall A; Poster Bd # 304) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2518;
P1
Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025 LBL-007 plus toripalimab continued to show promising antitumor activity and manageable safety profile in patients with treatment-na
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open, Monotherapy: BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 9, 2023
P2, N=90, Recruiting, Sponsor: BeiGene
LBL-007 plus toripalimab continued to show promising antitumor activity and manageable safety profile in patients with treatment-na Not yet recruiting --> Recruiting
- || Tevimbra (tislelizumab-jsgr) / BeiGene
Trial initiation date, Monotherapy: BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 31, 2023
P2, N=90, Not yet recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Initiation date: Dec 2022 --> Mar 2023
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Jan 11, 2023
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Initiation date: Dec 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment open, Mismatch repair, IO biomarker: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 23, 2022
P1b/2, N=202, Recruiting, Sponsor: BeiGene
Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Aug 2024 Not yet recruiting --> Recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial initiation date, Mismatch repair, IO biomarker: Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2022
P1b/2, N=202, Not yet recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Initiation date: Nov 2022 --> Feb 2023
- ||||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial: BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 2, 2022
P2, N=300, Not yet recruiting, Sponsor: BeiGene
- | alcestobart (LBL-007) / BeiGene
Trial completion date: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Nov 23, 2022
P1/2, N=200, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Initiation date: Nov 2022 --> Feb 2023 Trial completion date: Jul 2023 --> Apr 2023
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial, Monotherapy: BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 13, 2022
P2, N=90, Not yet recruiting, Sponsor: BeiGene
- |||| alcestobart (LBL-007) / BeiGene
Enrollment open: LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov) - Sep 2, 2022
P1/2, N=410, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Trial completion date: Jul 2023 --> Apr 2023 Not yet recruiting --> Recruiting
- ||| surzebiclimab (BGB-A425) / BeiGene, Tevimbra (tislelizumab-jsgr) / BeiGene, alcestobart (LBL-007) / BeiGene
Enrollment change, Trial completion date, Trial primary completion date: BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - Aug 31, 2022
P1/2, N=358, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026